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Abstract 
With the continued growth in the numbers of nurse practitioners and certified 
nurse-midwives, more and more women will receive prenatal care from advanced 
practice nurses. The purpose of this research was to assess the routine screening practices 
of advance practice nurses providing prenatal care and to compare those practices with 
current guidelines. The study focused on five areas of prenatal screening: bacterial 
vaginosis, group B streptococcus, gestational diabetes, maternal serum markers, and fetal 
movement monitoring. The interaction model of client health behavior by Cheryl Cox, 
specifically professional-technical competencies, part of the client-professional element 
of the model, provided the theoretical :framework for this study. 
The sample was obtained :from two major nursing organizations involved in 
prenatal care: the National Association ofNurse Practitioners in Women's Health and the 
American College ofNurse-Midwives. A random sample of250 members from each 
organization was sent a postcard explaining the study and directing them to the online 
survey. 
In four out of five screening areas, there was no significant difference in the 
screening practices ofNPs and CNMs. Bacterial vaginosis was the only screening with a 
significant difference. There was inconsistency with what the advanced practice nurses 
state they do and current guidelines with respect to screening for group B streptococcus 
and maternal serum markers. 
Chapter One: Introduction 
According to the Centers for Disease Control (CDC) National Vital Statistics 
System, approximately 4,138,349 infants were born in 2005 (CDC, 2008). Prenatal care 
for these births is provided not only by physicians, but also by, advanced practice nurses, 
including nurse practitioners and certified nurse-midwives. 
Every pregnant woman should receive quality prenatal care to assess and treat 
risks to both the mother and fetus. Early identification of high-risk pregnancies allows 
clinicians to provide appropriate care to decrease morbidity and mortality. "Women who 
receive early and regular prenatal care are more likely to have healthier infants" 
(American Academy of Pediatrics [ AAP] & American College of Obstetricians and 
Gynecologists [ACOG], 2007, p. 87). All prenatal care providers should be qualified to 
provide appropriate education, risk assessment, and treatment to this population. 
Organizations such as the ACOG, the CDC, the American Diabetes Association (ADA) 
and the United States Preventive Services Task Force (USPSTF) provide guidelines for 
prenatal care which are based on extensive research and evidence based practice. These 
guidelines include recommended prenatal screening practices. 
Some routine testing provided in prenatal care is generally accepted as 
appropriate care. These tests include hematocrit and hemoglobin levels, urinalysis, 
determination of blood group and Rh type, antibody screen, determination of immunity to 
rubella virus, syphilis screen, chlamydia screen, cervical cytology, human 
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immunodeficiency virus antibody testing, hepatitis testing, group B streptococcus screen, 
and maternal serum markers (AAP & ACOG, 2008). For some other screenings, 
including screening for bacterial vaginosis, gestational diabetes, and fetal movement 
monitoring, questions remain as to whether evidence supports these tests and monitoring 
in all pregnant women. 
Advanced practice nurses (APNs) delivering care to pregnant women are 
qualified to provide appropriate education, risk assessment, and treatment to this 
population. Nurse practitioners (NPs) were first trained in the area of pediatrics when 
Loretta Ford and Dr. Henry Silver started the pediatric nurse practitioner program at the 
University of Colorado in 1965 in response to the need for primary care for children in 
urban and underserved areas (Pulcini & Wagner, 2002). Since then, nurse practitioner 
programs have evolved to include all types of specialties such as geriatrics, acute care, 
neonatal, psychiatric, women's health, and family practice, to name just a few. In 
addition, many NPs educated in areas such as adult health or primary care will actually 
practice in more specialized areas such as cardiac, dermatology, or obstetrics. These 
nurses are tasked with developing additional competencies in these specialized areas. 
Most states currently require NPs to have master's level education and national 
certification in order to practice. Currently there are more than 300 master's level NP 
programs (Bureau of Labor Statistics, 2007), and more than 140,000 NPs in the United 
States (Health Resources and Services Administration [HRSA], 2004). 
Midwives have been in practice in the United States for many years. The first 
formal education of nurse-midwives in the United States began with the School for the 
Association for the Promotion and Standardization of Midwifery in 1932 and the Frontier 
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Graduate School ofMidwifery in 1939 (Burst & Thompson, 2003). Midwives initially 
practiced in homes, mostly for women of low socioeconomic status. In 1953, midwives 
first started practice in university-affiliated hospitals, which opened the door to education 
within a university (Burst & Thompson, 2003). As of2006, there were 39 accredited 
nurse-midwifery programs in the United States (Bureau of Labor Statistics, 2007) and 
more than 13,000 nurse-midwives (HRSA, 2004). Of these nurse-midwives, only 7,037 
were actually employed as nurse-midwives (HRSA, 2004). 
Currently, there is a lack of information regarding obstetrical practices ofNPs and 
CNMs. As more nurses become advance practice nurses, and more clients seek care from 
advanced practice nurses, it will be important to show that advance practice nurses are 
providing quality prenatal screening for risk factors and complications in pregnancy. 
Purpose 
The purpose of this study was to assess routine obstetrical screening practices of 
NPs and CNMs who routinely provide prenatal care and to compare those practices with 
current guidelines. The five specific areas chosen as a focus were bacterial vaginosis, 
group B streptococcus, gestational diabetes mellitus, maternal serum markers, and fetal 
movement monitoring. 
Theoretical Framework 
The theoretical framework chosen for this study was the interaction model of 
client health behavior (IMCHB) by Cheryl Cox. The IMCHB has three major elements: 
client singularity, the client-provider relationship, and subsequent client health care 
behavior (Cox, 1982). Use ofthe model assumes that clients are both capable of and 
competent to make choices about their health care behavior and advocates for maximum 
control by the client in making such choices, within their limitations (Cox, 1982). 
Client singularity. Client singularity is composed of the client's background 
variables, motivation, appraisal of health care concerns, and the affective response to 
health care concerns. Each client has a unique combination of these variables, which 
should guide health care professionals in their approach and plan (Cox, 1982). 
The background variables include demographic characteristics, financial resources, 
influence of client's social group, previous experiences with health care, environmental 
resources and availability of health care facilities. These are in constant interaction with 
each other to produce each client's unique health behavior (Cox, 1982). 
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The second aspect of client singularity, motivation, is defined by Cox (1982) as 
the "choice, desire, and the need for competency and self-determinism as causal factors 
in behavior" (p. 49). Motivation is preceded by background variables, cognitive appraisal 
and affective response. When clients are allowed to be active participants in their health 
care choices, this reinforces their motivation to continue the positive behavior. 
Cognitive appraisal refers to the client's interpretation of their health, their 
choices and the relationship between them and the health care provider (Cox, 1982). 
Clients will act according to their perception of reality, which may or may not be the 
objective reality. Once again, a client's background variables will influence their 
cognitive appraisal. 
The last element of client singularity is affective response to health concerns 
(Cox, 1982). Clients' behaviors are not only based on rational, cognitive thought, but also 
emotions. Both negative and positive emotions can affect future behaviors. If a client has 
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a negative experience during an exam, it may lead to an effective response of fear, thus 
preventing them from having that exam in the future. All four aspects of client singularity 
need to be assessed and addressed in order to provide a positive health care experience 
for the client. 
Client-professional interaction. The client-professional interaction is the second 
element of the IMCHB model. It focuses on the "continuous reciprocal interaction 
between aspects of the client's singularity, the interaction, and the health care outcomes" 
(Cox, 1982, p. 51). There are four components within client-professional interaction: 
provision of health information, affective support, decisional control, and professional-
technical competencies. Each of these components, along with the client's singularity and 
health care need, define the interaction between the client and health care professional. 
Health information is necessary for positive change in health behaviors, but is not 
enough on its own (Cox, 1982). Information concerning the details of the problem as well 
as what can or cannot be done provide the client with knowledge necessary to make 
appropriate decisions, provided the information is not too great or too small. The client's 
relationship with the health care provider, perceived control over the situation, and 
client's singularity, will determine how the client processes and uses the provided 
information. 
The second component of client-professional relationship is affective component, 
which refers to the client's level of emotional arousal. Depending on the client's 
singularity, the affective response could, interventions may need to first reduce the level 
of emotional arousal in order for any other intervention to be effective. To provide clients 
with too much affective support, if that type of support is not needed, may also lead to 
patient dissatisfaction (Cox, 1982). 
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Decisional control is an important element since it "increases the client's sense of 
self-efficacy and facilitates commitment to health-relevant behaviors (Cox, 1982, p. 52). 
Decisional control is inter-related to the other elements of affective support and health 
information. A patient may be emotionally aroused to the extent that they may not be able 
to provide decisional control. If inaccurate or inappropriate levels ofknowledge are 
provided, the client may not be able to provide decisional control. The goal is to allow the 
patient to have maximum decisional control as the situation warrants (Cox, 1982). 
The last element, professional-technical competencies, is related to the other 
elements in that "the greater the client's need for technical skills from the provider, the 
less the need for decisional control" (Cox, 1982, p. 53). Depending on the client's health 
state, the need for affective and information will vary. In order to increase the clients' 
sense of self-determination, their own abilities should be brought into play as the need for 
technical intervention decreases (Cox, 1982). 
Health outcomes. The last component ofthe IMCHB is health outcomes (Cox, 
1982). Health outcomes are measured by health behaviors or a health state that results 
from that behavior. According to Cox (1982), health outcomes consist of"five distinctive 
variables: utilization of health care services, clinical health-status indicators, severity of 
recommended-care regimen, and satisfaction with care" (p.53). The variables are all 
useful depending on the purpose, and will vary in accordance with the objective of the 
study. 
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This study focuses on the client-professional interaction, specifically professional-
technical competencies. In pregnancy, clients rely on health care providers to provide a 
high level of technical skills and monitoring to provide important information that may 
affect decisions made by the client. This study will focus on specific aspects of 
monitoring (screening) done by advance practice nurses. 
Table 1.1 
Interaction Model of Client Health Behavior as Used in the Present Study 
Client singularity 
Demographic 
characteristics 
Social influence 
Previous health 
care experience 
Environmental 
resources 
Intrinsic 
motivation 
Cognitive 
appraisal 
Affective 
response 
Client-professional 
interaction 
Affective support 
Health information 
Decisional control 
Professional-
Technical 
Competencies: 
Prenatal Screening 
Health Outcomes 
Utilization of 
health care services 
Clinical health 
status indicators 
Severity of health 
care problems 
Adherence to the 
recommended care 
regimen 
Satisfaction with 
care 
Note. From "An interaction model of client health behavior: Theoretical prescription for 
nursing," by C.L. Cox, 1982, Advances in Nursing Science, 5(1), p. 47. 
Chapter Two: Literature Review 
The literature review will provide background information on the five areas of 
this study: bacterial vaginosis, group B streptococcus, gestational diabetes, maternal 
serum markers, and fetal movement monitoring. Screening recommendations from the 
CDC, USPSTF, ACOG, and the ADA will be presented, as well as appropriate 
information from current literature. 
Bacterial Vaginosis 
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Bacterial vaginosis (BV) is a common infection in the female genital tract 
resulting from the overgrowth of normal flora, such as Gardnerella vaginalis, 
mycoplasmata, and anaerobes, and a reduction of hydrogen peroxide-producing 
lactobacillus (Nygren et al., 2008). Although many women with BV are asymptomatic, 
BV commonly presents with a thin white discharge (CDC, 2006). The diagnosis is made 
based on the presence of two of three signs: amine odor before or after the application of 
10% KOH, the presence of clue cells on microscopic exam and a vaginal fluid pH greater 
than 4.5 (CDC, 2006). 
BV in the general population is generally a benign condition, but has been 
associated with pelvic inflammatory disease, endometritis and vaginal cuff cellulitis after 
invasive procedures (CDC, 2006). However, in pregnant women, BV is associated with 
adverse outcomes including "premature rupture of membranes, preterm labor, preterm 
birth, intra-amniotic infection, and postpartum endometritis" (CDC, 2006, p. 51). The 
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prevalence rate ofBV in pregnant women varies from 9% to 23%, but is not well studied 
in community settings (Nygren et al., 2008). 
Two organizations, the CDC and USPSTF have made recommendations regarding 
BV screening and treatment (CDC, 2006; USPSTF, 2008). The differences in the 
recommendations are slight because the evidence is inconclusive. A 2007 Cochrane 
review concluded that, while there is sufficient evidence that BV is associated with an 
increased risk for preterm birth, there is still not enough evidence to conclude whether 
screening and treatment is beneficial in reducing poor perinatal outcomes (McDonald, 
Brocklehurst, & Gordon, 2007) 
The CDC recommends screening for BV during the first prenatal visit and 
treatment of all symptomatic pregnant women (CDC, 2006). In women who have 
previously delivered a preterm infant and are at high risk for premature delivery, 
treatment of asymptomatic BV is recommended. The treatment of choice for BV is 
metronidazole 500 mg by mouth twice a day for seven days, or metronidazole 250 mg by 
mouth three times a day for seven days, or clindamycin 300 mg by mouth twice a day for 
seven days (CDC, 2006). The USPSTF, on the other hand, does not recommend for or 
against routine screening for BV in pregnancy, even those at high risk for preterm 
delivery, stating that there is insufficient evidence on the harms and benefits of screening 
and treatment (USPSTF, 2008). 
BV screening can be done several ways. The gold standard for detecting BV is the 
gram stain, which allows the clinician to observe different gram negative and gram 
positive rods which are characteristic ofBV (CDC, 2006). BV can also be diagnosed 
using clinical criteria, which requires three of the following symptoms: 
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1. Homogeneous, thin, white discharge that smoothly coats the vaginal 
walls 
2. presence of clue cells on microscopic examination 
3. pH of vaginal fluid >4.5 
4. a fishy odor ofvaginal discharge before or after addition of 10% KOH 
(i.e., the whiff test). (CDC, 2006) 
Commercially available tests are also available for the diagnosis of BV which detect 
elevated pH and trimethylamine or prolineaminopeptidase (CDC, 2006). 
Group B Streptococcus 
Group B Streptococcus (GBS) is a gram positive bacteria that colonizes the 
vaginal-rectal area in 10-30% of pregnant women (Schrag, Forwitz, Fultz-Butts & 
Schuchat, 2002). Women who are colonized with GBS are at risk for post-partum 
infections such as urinary tract infection, arnnionitis, endometritis, sepsis, and meningitis 
(Schrag et al., 2002). In newborns, GBS sepsis can be the result of vertical transmission 
from the mother during labor or delivery, nosocomial infection, or community-acquired 
infection. Infection in the newborn can cause sepsis, pneumonia, and meningitis (AAP & 
ACOG, 2007). Even with preventive strategies in place, "GBS disease remains a leading 
infectious cause of morbidity and mortality among newborns in the United States" 
(Schrag et al., 2002, p. 2). Both the CDC and ACOG recommend screening all pregnant 
women by vaginal and rectal cultures at 35-37 weeks gestation (AAP & ACOG, 2007; 
Schrag et al., 2002). (See table 2.1) 
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Table 2.1 
Indications for Intrapartum Antibiotic Prophylaxis to Prevent Perinatal GBS Disease 
Vaginal and rectal GBS screening cultures at 35-37 weeks of gestation for ALL pregnant women 
(unless patient had GBS bacteriuria during the current pregnancy or a previous infant with 
invasive GBS disease) 
Intrapartum prophylaxis indicated 
·Previous infant with invasive GBS disease 
·GBS bacteriuria during current pregnancy 
·Positive GBS screening culture during current 
pregnancy (unless a planned cesarean delivery, 
in the absence of labor or amniotic membrane 
rupture, is performed) 
·Unknown GBS status (culture not done, 
incomplete, or results unknown) and any of the 
following: 
-Delivery at less than 37 weeks of gestation 
-Amniotic membrane rupture of 18 hours or 
greater 
-Intrapartum temperature at 100.4°F or greater 
(38.8°C or greater) 
Intrapartum prophylaxis not 
indicated 
·Previous pregnancy with a 
positive GBS screening culture 
(unless a culture was also positive 
during the current pregnancy) 
·Planned cesarean delivery 
performed in the absence of labor 
or membrane rupture (regardless of 
maternal GBS culture status) 
·Negative vaginal and rectal GBS 
screening culture result in late 
gestation during the current 
pregnancy, regardless of 
intrapartum risk factors 
Note. From Guidelines for Perinatal Care (61ll ed.), by American Academy of Pediatrics 
and American College of Obstetricians and Gynecologists, 2007, p. 329. 
Both CDC and ACOG use the same recommendations for intrapartum 
antimicrobial prophylaxis for GBS. The recommended regimen, provided the mother is 
not allergic to penicillin is Penicillin G, 5 million units intravenous (IV) initial dose, 
followed by 2.5 million units IV every four hours until delivery. An alternative regimen 
is 2 grams ampicillin IV initial dose, followed by 1 gram IV every four hours until 
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delivery. For women who are allergic to penicillin, recommendations are based on 
whether there is a high risk for anaphylaxis. Women who are not at high risk for 
anaphylaxis can receive cefazolin 2 grams IV initial dose, followed by 1 gram every eight 
hours until delivery. In women who are at high risk for anaphylaxis, the 
recommendations depend upon whether the GBS is susceptible to clindamycin and 
erythromycin or resistant. If the GBS is susceptible, then clindamycin 900 milligrams IV 
every eight hours until delivery or erythromycin 500 milligrams IV every six hours until 
delivery may be used. In patients with resistant GBS or if susceptibility is unknown, then 
vancomycin 1 gram IV every twelve hours until delivery should be used (Schrag et al., 
2002; AAP & ACOG, 2007). 
Gestational Diabetes 
The American Diabetes Association (ADA) defines gestational diabetes mellitus 
(GDM) as "any degree of glucose intolerance with onset or first recognition during 
pregnancy" (ADA, 2008, p. 15). Depending on the population studied and diagnostic 
tests used, occurrence of GDM ranges from 1-14%, with an average of 7% in the general 
population (ADA, 2008). 
The ADA (2008) and ACOG (AAP & ACOG, 2007) recommend routine 
screening for GDM by risk factor analysis (patient history and clinical risk factors) and 
oral glucose tolerance testing when indicated. In addition, women diagnosed with GDM 
should also be screened 6-12 weeks after birth due to increased risk for type-2 diabetes 
(ADA, 2008). Pregnant women who meet all of the following requirements are at very 
low risk for GDM and may not need glucose challenge screening: 
1. Age younger than 25 years 
2. Not a member of a racial or ethnic group with a high prevalence of diabetes 
mellitus (i.e., not Hispanic, African, Native American, South or East Asian, or 
Pacific Islands ancestry) 
3. Body mass index of25 or less 
4. No history of abnormal glucose tolerance 
5. No history of adverse pregnancy outcomes usually associated with GDM 
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6. No known diabetes mellitus in first degree relative (AAP & ACOG, 2007, p 104). 
In contrast to the recommendations of ACOG and the ADA, the USPSTF states 
there is insufficient evidence to recommend for or against routine screening for 
gestational diabetes (USPSTF, 2008). A 2003 Cochrane review on treatments for GDM 
concluded that there is not enough evidence on beneficial effects oftreatments for 
glucose intolerance on perinatal outcomes (Tuffnell, West, & Walkinshaw, 2003). 
Recommendations for the screening of GDM vary according to the source. ACOG 
recommends screening for GDM at 24 to 28 weeks gestation, using a 50 gram 1 hour oral 
glucose challenge. The test may be administered regardless of the time of the last meal. 
Either threshold of 130 mg/dl or 140 mg/dl may be used, although 140 mg/dl has less 
sensitivity than 130 mg/dl, but fewer false positives. Women who fail the 1 hour oral 
glucose challenge will be further evaluated using the 3 hour oral glucose tolerance test. 
ACOG recognizes two diagnostic criteria for the 3 hour oral glucose tolerance test: 
Carpenter/Coustan Conversion and National Diabetes Data Group Conversion. A positive 
diagnosis of GDM requires that two or more thresholds be met or exceeded (ACOG, 
2001 ). Table 2.2 presents the two diagnostic criteria. 
The ADA guidelines differ slightly from ACOG for GDM screening and for 
normal parameters. The ADA recommends risk assessment for GDM at the first prenatal 
visit. Women who have severe obesity, previous history ofGDM or large-for-gestational-
age infant, glycosuria, diagnosis of polycystic ovarian syndrome, or strong family history 
Table 2.2 
Two Diagnostic Criteria For Gestational Diabetes Mellitus 
Status Plasma or Serum Glucose Level Plasma Level 
Carpenter/Coustan Conversion National Diabetes Data Group 
Fasting 95 mg/dl 105 mg/dl 
One hour 180 mg/dl 190 mg/dl 
Two hours 155 mg/dl 165 mg/dl 
Three hours 140 mg/dl 145 mg/dl 
Note. From "ACOG Practice Bulletin. Clinical Management Guidelines for 
Obstetricians-Gynecologists. Number 30," by American College of Obstetricians and 
Gynecologists Committee on Practice Guidelines- Obstetrics, 2001, Obstetrics and 
Gynecology 98(3), p. 529. 
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of type 2 diabetes should be tested as soon as possible. Screening thresholds at this stage 
consist of a fasting (nothing by mouth for previous eight hours) plasma glucose greater 
than or equal to 126 mg/dl; or symptoms of hyperglycemia (polyuria, polydypsia, 
unexplained weight loss) and a causal (any time of day regardless of intake) plasma 
glucose greater than or equal to 200 mg/dl; or two hour plasma glucose greater than or 
equal to 200 mg/dl during an oral glucose tolerance test using a 75 grams glucose 
loading. 
All women who do not meet the six previously listed criteria for very low risk 
should undergo GDM testing at 24 to 28 weeks gestation, including higher risk women 
who were tested earlier in pregnancy (ADA, 2008). Initial screening is performed by 
measuring serum or plasma blood glucose levels one hour after a 50 gram glucose load. 
Depending on the clinician, women whose glucose are greater than or equal to either 130 
mg/dl or 140 mg/dl will need further testing using the 3 hour oral glucose tolerance test. 
According to the ADA, using a threshold of 140 mg/dl will identify approximately 80% 
of women with GDM while a threshold of 130 mg/dl will identify approximately 90% of 
women with GDM. GDM is diagnosed if at least two of the following thresholds are met 
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or exceeded: fasting~ 95 mg/dl, one hour~ 180 mg/dl, two hour~ 155 mg/dl, three hour 
~ 140 mg/dl (ADA, 2008). 
Maternal Serum Screening 
Maternal serum screening is used in pregnant women to identify increased risk for 
trisomy 21 and 18 defects, neural tube defects (NTDs ), and other aneuploidies (abnormal 
number of chromosomes). The tests consist of first-trimester combined serum screening 
with ultrasound assessment of fetal nuchal translucency, second-trimester triple or 
quadruple marker serum screening, and combined first and second-trimester fetal 
aneuploidy screening approaches. All women receiving prenatal care before 20 weeks 
gestation should receive screening for aneuploidy, regardless of age (AAP & ACOG, 
2007). Maternal serum screening is used to detect a population of women who are at 
increased risk for Down's syndrome and other aneuploidies, but is not diagnostic. 
Women with positive screens should be offered diagnostic testing such as chorionic villus 
sampling (CVS) or amniocentesis. Maternal serum screening helps to decrease the 
number of women who need to undergo invasive procedures such as CVS or 
amniocentesis that put the fetus at risk. 
First- trimester serum screening consists of pregnancy associated plasma 
protein-A and free ~-hCG. Women who select this option should also be offered either 
ultrasound screening for neural tube defects (NTDs) or second-trimester maternal serum 
alpha-fetoprotein (MSAFP) testing. First trimester screening is generally performed at 
10-13 weeks gestation. 
Second-trimester triple screen consists of AFP, estriol, and ~-hCG, while 
quadruple screen consists of the previous three tests plus inhibin-A. Second-trimester 
testing should be performed at 15-20 weeks gestation (AAP & ACOG, 2007). 
Fetal Movement Monitoring 
16 
Fetal movement monitoring (FMM), also referred to as fetal kick count, is the 
counting of fetal movements to assess the condition of the baby (Mangesi & Hofmeyr, 
2007). In the 1970s and 1980s, FMM was a popular method for screening fetal well 
being. However, after research published by the Lancet in 1989 indicating that FMM did 
not reduce stillbirths, interest and research in FMM seemed to decline (Froen, 2004). In 
2004 a literature review performed by Froen indicated that FMM reduces perinatal 
mortality. A Cochrane review published in 2007 reports that there is "not enough 
evidence to influence practice" (Mangesi & Hofmeyr, 2007, p. 1). Of particular concern 
is that there are no trials comparing fetal movement counting with no fetal movement 
counting. Both of these reviews acknowledge the need for more research. ACOG (2007) 
recognizes that decreased fetal movement may precede fetal death and suggest daily 
monitoring after 28 weeks gestation by counting ten movements in a two hour period. 
The literature reviewed seems to acknowledge two main methods of counting 
fetal movement: the Sadovsky method and the Cardiff count-to-ten method. Although 
several methods are described, they all seem to be variations of these two methods. The 
Sadovsky method has women count four fetal movements three times a day for one hour 
after meals (Freda et al., 1993). If four fetal movements are not felt in one hour, then the 
woman should count for one more hour. If at that time four movements have not been 
felt, the woman is advised to call her provider. The Cardiff count-to-ten method has 
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women count the first ten movements of the day for up to twelve hours. lften movements 
are not felt in twelve hours, the woman is advised to contact her provider (Freda et al., 
1993). Other common methods are listed in table 2.3. The variations in these methods 
show that an optimal method, number of movements, recording period, or definition of 
decreased fetal movement has not been determined. 
Table 2.3 
Techniques for Monitoring Perceived Fetal Motion 
Study Definition of Decreased Fetal 
Activity 
Pearson & Weaver 
(1976) 
Sadovsky & Palishuk 
(1977) 
Neldham (1980) 
<10 movements/12 hour 
< 2 movements/hour 
:S 3 movements/hour 
O'Leary & 0-5 movements/30 minutes for each 
Andrinopoulos (1981) of the three 30-minute periods 
Harper et al. (1981) Complete cessation 
Leader et al. (1981) 1 day of no movements or 2 
successive days/week in which 
there are <1 0 movements/hour 
Recording Periods 
12 hours (9:00 AM-9:00 
PM) daily 
30 minutes to 1 hour, 
twice or three times daily 
One 2-hour period, three 
times weekly 
Three 30-minute periods, 
daily 
Three 1-hour periods, 
daily 
30 minutes, four times 
daily 
Rayburn (1982) <3 movements/hour for 2 > 1 hour (when 
consecutive hours convenient) 
Picquadio & Moore <1 0 movements/hour for 2 Count to 10 movements 
(1998) consecutive hours (no time restriction) 
Note. From "Antenatal Evaluation of the Fetus Using Fetal Movement Monitoring," by 
M. Valazquez and W. Rayburn, 2002, Clinical Obstetrics and Gynecology, 45(4), p. 
1000. 
Chapter Three: Method 
This chapter describes the methods used for this level II comparative study of 
routine obstetrical screening practices ofNPs and CNMs. 
Sample Population 
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The sample was a random sample ofNPs obtained from the National Association 
ofNurse Practitioners in Women's Health (NPWH) and CNMs from the American 
College of Nurse-Midwives (ACNM). A random sample of250 names of current, active 
members was obtained from each organization. 
Instrument 
The instrument used for this study was a 37-item survey previously developed for 
another study. The survey was modified based on the pilot study data and to reflect the 
current state of the science with respect to screening. The survey has three sections: 
demographic data, general obstetric screening practices, and specific screening practices 
in the five areas of interest: maternal serum markers, bacterial vaginosis, group B 
streptococcus, gestational diabetes, and fetal kick count (see Appendix A). Content 
validity of the survey was verified with review by two experts in prenatal care. 
Procedures for Data Collection 
Human subject approval was obtained from the Institutional Review Board of the 
University ofNorth Florida (see Appendix B). A postcard was sent to the NPWH and 
ACNM members requesting them to participate in the survey (see Appendix C). The 
postcard contained the URL for the University of North Florida Brooks College of 
Health, which contained a link directly to the survey. The survey itself was deployed 
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using Survey Monkey, a web site used to create surveys, then collect and tabulate the 
data. The web site is secure and does not use any information for its own purposes. 
Survey Monkey has met Safe Harbor requirements and is on the Safe Harbor list of 
companies. The online survey was open for six weeks after the postcards were mailed. 
Participants were also given the option to receive a paper copy of the survey via the 
United States Postal Service, with a self addressed stamped envelope to return the survey. 
Chapter Four: Results 
This chapter presents the results of this level II comparative study. The results 
include the demographic characteristics of the sample as well as the screening practices 
ofNPs and CNMs. 
Characteristics of the Sample 
20 
Seventy-six individuals completed the survey between August 4, 2008 and 
September 15, 2008. One individual requested and completed a hard copy ofthe survey. 
Three of the completed surveys were not usable: two individuals did not provide prenatal 
care and one only provided care up to 8 weeks gestation. This left 73 usable surveys. 
Of the 73 individuals, 72 were female. The age range was 28 to 63 (M = 46.34, 
SD = 9.99). The majority of the respondents (55, 76.4%) held a master's degree in 
nursing, were certified in advanced practice nursing (72, 98.6%) and were practicing 
CNMs ( 49, 67.1% ). Respondents reported seeing 10 to 4000 pregnant patients in their 
practices annually (M = 647.58, SD = 877.56). The majority (62, 84.9%) were in practice 
with OB/GYN physician(s) and other APNs (nurse practitioners and/or nurse-midwives). 
Most (47, 64.4%) belong to one or more advanced practice nursing organizations. Table 
4.1 presents the details of the sample characteristics. 
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Table 4.1 
Characteristics of This Samp_le of APNs and APN Practice 
Characteristic N % 
Highest Level of Education* (N=72) 
Certificate 5 6.9 
Bachelors in nursing 2 2.8 
Bachelors in another field 1 1.4 
Masters in nursing 55 76.4 
Masters in another field 6 8.3 
Doctorate in nursing 2 2.8 
Doctorate in another field 2 2.8 
Advanced Practice Specialty* (N=73) 
Family nurse practitioner 3 4.1 
Nurse-midwife 49 67.1 
Women's health nurse 12ractitioner 23 31.5 
Advanced Practice Certification* (N=73) 
American College ofNurse-Midwives 44 60.3 
National Certification Corporation 24 32.8 
American Nurse Credentialing Center 4 5.5 
American Academy ofNurse Practitioners 2 2.7 
No certification 1 1.4 
Type ofPractice Setting (N=73) 
With OB/GYN physician(s) 15 20.5 
With OB/GYN physician(s) and other APNs 47 64.4 
With Family Practice physician(s) 1 1.4 
With Family Practice physician(s) and other APNs 5 6.8 
With other APNs and CNMs 5 6.8 
*Some individuals chose more than one category 
In general, routine prenatal diagnostic screening and testing was performed by the 
majority ofthe sample (see Table 4.2). Respondents indicated that several screening and 
diagnostic tests are done within their own office setting: glucose testing (55, 73.2%), 
hemoglobin testing (52, 73.2%), non-stress testing (44, 60.3%), and OB ultrasound (44, 
60.3%). 
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Table 4.2 
Routine Obstetrical Screening N = 73 
Test Routinely First trimester Second Third Trimester 
ordered trimester 
N % N % N % N % 
CBC 64 87.7 45 61.6 1 1.4 34 46.6 
H&H 30 41.1 10 13.7 1 1.4 25 34.2 
RPR 63 86.3 43 58.9 15 20.5 
Chlamydia culture 57 78.1 39 53.4 19 26 
Gonorrhea culture 57 78.1 39 53.4 19 26 
HSV 7 9.6 5 6.8 5 6.8 
HIV 58 79.5 39 53.4 14 19.2 
Pap 60 82.2 40 54.8 2 2.7 
Urine 56 76.7 37 50.7 3 4.1 -~1-.. 
As to the five specific screenings, 20 (27.4%) of the respondents have a written 
protocol for bacterial vaginosis screening, 55 (75.3%) for Group B strep screening, 54 
(74%) for gestational diabetes screening, 43 (58.9%) for maternal serum markers and 33 
(45.2%) for fetal kick count monitoring (see Table 4.3). 
Table 4.3 
Screening for Five Specific Conditions 
Written protocol Routinely ordered Screening CNMs (N=49) NPs (N=24) 
N % N % N % 
Bacterial vaginosis 20 27.4 9 18.4 10 41.7 
Group Beta Strep 55 75.3 49 100.0 24 100.0 
Gestational diabetes mellitus 54 74.0 48 98.0 24 100.0 
Maternal serum markers 43 58.9 26 53.1 13 54.2 
Fetal kick counts 33 45.2 29 59.2 13 54.2 
Bacterial Vaginosis 
Few (19, 26.0%) respondents report routinely screening for BV. There was a 
significant difference in routine screening between CNMs and NPs with NPs screening 
more frequently (Chi square= 4.54, p =.033). Most of those who do screen (14, 77.8%) 
do so in the first trimester. Other responses include screening in the first and third 
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trimester (2, 11.1%) and at the first visit (2, 11.1% ). The most commonly used diagnostic 
parameters are the presence of clue cells (16, 84.2%) and whiff(amine) test{14, 73.7%). 
Culture is used by 5 (26.3%) and nitrazine paper by 3 (15.8%). Respondents who do not 
routinely screen for BV stated screening was performed if the patient had complaints or 
signs and symptoms ofBV (38, 71.7%), patient had signs and symptoms and preterm 
labor (14, 26.4%), or if the patient had history or preterm labor (1, 1.9%). Of the 17 
respondents who answered the question regarding treatment for BV, 12 (70.6%) use 
metronidazole (see table 4.4). 
Table 4.4 
Treatment Regimens for BV 
-
First Second 
Treatment trimester trimester 
N=15 % N=l3 % 
Nothing 4 26.7 0 0 
Metronidazole PO 500 mg TID x 7 days 3 20.0 3 23.1 
Metrogel 1 applicator per vagina q HS x 5 days 2 13.3 1 7.7 
Metronidazole PO 250 mg TID x 7 days 2 13.3 4 30.8 
Metronidazole PO 500 mg BID x 7 days 1 6.7 2 15.4 
Metronidazole PO 1 gm x 1 dose 1 6.7 1 7.7 
Clindamycin PO 300 mg BID x 7 days 1 6.7 1 7.7 
Clindamycin Cream 1 applicator p.v. qhs x 7 days 1 6.7 0 0 
Metronidazole PO 2 gm x 1 dose 0 0 1 7.7 
Group B Streptococcus 
All respondents indicated they routinely screen for GBS. Forty-six (63%) use the 
culture based approach, 2 (2.7%) use the risk factor approach, and 20 (27.4%) use both 
approaches. See table 4.6 for risk factors considered in the risk factor approach. 
24 
Table 4.5 
Risk Factors to Screen for GBS 
-
Condition N Percent 
Previous child affected with GBS 17 23.3 
Positive GBS culture in previous _pregnancy 11 15.1 
Multifetal gestation 1 1.4 
Previous history of preterm labor or PROM 8 11.0 
GBS UTI in pregnancy 19 26.0 
Preterm labor or PROM 2 2.7 
The majority of respondents (39, 53.4%) perform GBS cultures at 36 weeks gestation, 
followed by 16 (21.9%) at 35 weeks, 3 (4.1%) at 34 weeks, 2 (2.7%) at 37 weeks and 1 
(1.4%) at 33 weeks. Most commonly, cultures are obtained from the vagina (65, 89.0%) 
and the anorectal area (67, 91.8%). Other areas included the cervix (4, 5.5%), urethra (4, 
5.5%), and the urine (1, 1.4%). Most respondents (65, 89.0%) treat positive GBS when 
the patient is in labor only. Four respondents (5.5%) treat at the time of the positive 
result and in labor. 
Gestational Diabetes Mellitus 
Seventy-two (98.6%) of the respondents routinely screen for GDM between 24 
and 28 weeks gestation. There was no significant difference in routine screening between 
CNMs and NPs (Chi square= .497, p = .481). Most screen for GDM at 28 weeks (36, 
51.4%) followed by 26 weeks (19, 27.1 %), 27 weeks (10, 14.3%), 24 weeks (4, 5.7%) 
and 25 weeks (1, 1.4%). The most common risk factors for early screening were a 
previous history of GDM and a history of macrosomia (see table 4.5). Respondents who 
did stated they did not routinely screen for GDM stated they screen only when risk 
factors are present (1, 1.4%). 
Table 4.6 
Risk Factors for Early Screening (before 28 weeks) for GDM 
Risk Factor 
Previous history of GDM 
History of macrosomia 
Obesity 
Family history of diabetes 
Previous unexplained fetal death 
Previous birth of infant with unexplained congenital abnormalities 
Glycosuria 
Advanced maternal age 
Recurrent yeast infections 
Metabolic syndrome or polycystic ovary disease 
Polyhydraminos 
Native American ethnicity 
N 
71 
60 
48 
45 
35 
23 
5 
2 
2 
1' 
1 
1 
Fifty-five (78.6 %) of the respondents use a non-fasting prep for the 1 hour 
glucose screen, 9 (12.9%) use a fasting prep and 5 (8.6%) use a specific diet. Most 
respondents (29, 40.8%) use 140 as the cutoff for the 1-hour screen. Twenty-two 
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% 
97.3 
82.2 
65.8 
61.6 
47.9 
31.5 
6.8 
2.7 
2.7 
1.4 
1.4 
1.4 
(31.0%) use less than 135, 16 (22.5%) use 135 and 3 (4.2%) use between 135 and 140. 
Respondents refer patients to a physician with an abnormal3 hour screen (27, 37%) and 
when insulin is started (20, 27.4%). Others answers included with an abnormal1 hour 
screen (1, 1.4%), with the start of oral medications (4, 5.6%), or when GDM is 
uncontrolled (1, 1.4%). Fifteen (20.5%) do not refer, but treat GDM themselves. Of the 
fifteen who do not refer, ten (66.7%) practice with OB/GYNs and other NPs/CNMs, four 
(26.7%) practice with other OB/GYNs, and one (6.7%) practices with family practice 
physicians and other NPs/CNMs. 
Maternal Serum Markers 
Thirty-nine respondents (53.4%) stated they routinely screen all patients for 
serum markers. There was no significant difference in routine screening between CNMs 
and NPs (Chi square= .008, p =.929). Of the practitioners who routinely screen, the 
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screening was done between 14 and 19 weeks with 16 weeks ( 12, 31.6%) and 18 weeks 
(15, 39.5%) being the most common. Most practitioners (30, 73.2%) ordered the quad 
screen. Other screenings ordered included the triple screen (5, 12.2%), triple screen with 
cystic fibrosis (2, 4.9%), alpha fetal protein (1, 2.4%), quad screen or integrated 
screening (1, 2.4%), quad screen, integrated screening and nuchal translucency (1, 2.4%). 
One respondent (2.4%) stated the test ordered would depend on the risk and when the 
patient presents for care. 
Most respondents (30, 88.2%) who do not routinely screen for maternal serum 
markers do screen at the patient's request or desire. One respondent (2.9%) screens at the 
patient's request or with perinatologist recommendations. Three respondents (8.8%) who 
do not routinely screen state screening for maternal serum markers is done on high risk 
patients such as advanced maternal age or personal history. 
Fetal Movement 
Fetal kick counts are routinely ordered by 42 (57.5%) ofthe respondents. There 
was no significant difference in routine screening between CNMs and NPs (Chi square= 
1.32, p =.517). Eighteen (24.7%) do not routinely order fetal kick counts and 13 (17.8%) 
only instruct patients to monitor fetal movement if there is a complication. Most 
advanced practice nurses have women monitor fetal movement during a particular week 
of gestation (see Table 4. 7). 
Instructions on how to monitor fetal movement were divided into five main 
categories, most of which involved some variation on count-to-ten (see Table 4.8). 
Instructions on what to do for decreased fetal movement included either reassessing the 
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movements before contacting the practitioner or contacting the practitioners right away. 
(see Table 4.8). 
Table 4.7 
When Fetal Movement Monitoring Begins 
Time 
Based on Gestational Age 
32-35 weeks gestation 
29-31 weeks gestation 
20-28 weeks gestation 
36-40 weeks gestation 
Based on Other Factors 
Only if decreased fetal movement 
Only if high risk 
Only post-term 
If fetus is small or concerned about movement 
Table 4.8 
Instruction for Fetal Movement Monitoring 
Instructions 
How To Count 
Count 5-10 movements in 30 minutes to 2 hours 
Eat, drink or lie down and count for 1 hour 
Time how long 10 movements take 
Be aware of movements and normal rhythm 
10 movements in 9-10 hours 
What to do for Decreased Movement 
N I% 
17 23.3 
16 21.9 
14 19.2 
6 8.2 
9 12.3 
7 9.6 
1 1.4 
1 1.4 
Eat, drink or lie down and re-attempt the count before calling the 
office, or going to the hospital 
Call the practitioner or go to the office or hospital without first 
re-attempting the count 
Re-monitor (with no other instructions given) 
Call only if no movement in 24 hours 
N I % 
46 65.7 
11 15.7 
7 10.0 
4 5.7 
2 2.9 
45 64.3 
23 32.9 
1 1.4 
1 1.4 
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Chapter Five: Discussion 
Many women receive prenatal care provided by NPs and CNMs every year. As 
more NPs and CNMs enter the healthcare industry, it is important that they provide 
appropriate care as described by agencies such as ACOG, ADA, and USPSTF. In areas 
where guidelines are not agreed upon or no guidelines exist, NPs and CNMs should guide 
their practice based on current evidence. 
This survey focused on five areas of screening during prenatal care: bacterial 
vaginosis, group B streptococcus, gestational diabetes, maternal serum screening, and 
fetal movement monitoring. In comparing NPs and CNMs, there was no statistical 
difference in practice except for screening for B V. More NPs ( 41.7%) routinely screened 
for BV than CNMs (18.4%) (Chi square= 4.54, p = .033). Of all five screenings, only 
GBS was routinely performed 100% by both NPs and CNMs followed by 98% who 
routinely screen for GDM. 
Implications for Practice 
Competence in screening practices is consistent with advanced nursing practice 
using the IMCHB model. In order to have such competence, APNs need to have intricate 
knowledge of the guidelines. When there are inconsistencies in the guidelines published 
by different organizations, such as in the case of obstetrical screening for BV, the 
provider relies on her/his clinical expertise and knowledge of the patient population to 
make judgments about routing screening. The CDC recommends screening for BV on the 
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first prenatal visit and treating all symptomatic pregnant women as well as asymptomatic 
women with previous history of preterm delivery (CDC, 2006). On the other hand, the 
USPSTF states there is insufficient evidence to make a recommendation for or against 
routine screening for BV, even in high risk pregnancies (USPSTF, 2008). In this sample, 
only 26% routinely screen their obstetrical patients for BV. Those who do not routinely 
screen appropriately test for BV for patient complaints or for pre-term labor. As far as 
treatment is concerned, the APN s prescribed metronidazole, which is the drug of choice, 
although the dosing of the therapy varied widely. It is interesting that only one indicated 
they prescribed clindamycin, since that is one of two treatment regimens that have 
demonstrated efficacy in reducing preterm birth, the other being metronidazole 500 mg 
BID x 7 days (CDC, 2006 ). 
Although 100% of this sample routinely screen for GBS in their obstetrical 
patients, there remain some inconsistencies in the timing and method of the screening as 
well as the timing of treatment. Both the CDC and ACOG guidelines specify the culture-
based approach which entails GBS screening at 35-37 weeks with vaginal and rectal 
cultures and antibiotic prophylaxis during labor for those with a positive culture (AAP & 
ACOG, 2007; Schrag et al., 2002). In this sample, only 63% actually screened in 
accordance with the guidelines. It may be that there is some misunderstanding of the 
difference between these two mutually exclusive approaches, since more than 25% 
indicated they used both approaches. 
Both the ADA (2008) and ACOG (2001) provide guidelines for GDM, while 
USPSTF (2008) and a Cochrane review (Tuffnell et al., 2003) state there is not sufficient 
evidence to recommend routine screening for GDM. Both ADA and ACOG recommend 
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routine screening at 24-28 weeks based on patient history and clinical risk factors using 
oral glucose tolerance testing (ADA, 2008; ACOG, 2001). More than 98% of the current 
sample routinely screens, and 98% of those who do screen do so at the appropriate time 
and using 130 mg/dl or 140 mg/dl as the threshold for further testing, as recommended. 
ADA (2008) recommends screening high risk patients at the first prenatal visit. ACOG 
(2007) states that women who meet specific criteria may not need screening for GDM. 
Neither of these elements was addressed in the current survey. 
ACOG (2007) recommends maternal serum screening all women who receive 
prenatal care prior to 20 weeks gestation for aneuploidy, regardless of maternal age. 
Despite this, only thirty-nine respondents (53.4%) stated they routinely screen for serum 
markers. Of the respondents who do not routinely screen, 88.2% stated they screen at the 
patient's request or desire. It is probable that these advanced practice nurses educate 
every patient on risks and benefits of screening, and then give them an option. Future 
research should explore this further. 
Fetal movement monitoring remains an interesting subject since there is so much 
conflicting literature and lack of quality research related to it. Although there are no 
specific recommendations for fetal movement monitoring, ACOG (2007) does recognize 
that a decrease in fetal movement may precede fetal death and suggests daily monitoring 
after 28 weeks gestation. Forty-two (57.5%) of the respondents stated that they ask their 
patients to monitor fetal movements. Most (88.7%) begin monitoring between 20 and 35 
weeks gestation. Although several different methods for monitoring fetal movement 
exist, most are some variation ofthe count-to-ten method, which 46 (65.7%) of the 
respondents stated they use. In reviewing the literature, no real specific instructions were 
found stating what women should do if they feel as if they are experiencing decreased 
fetal movements. Forty-five (64.3%) of the respondents stated they have the patient re-
attempt the count before any further action is taken. Twenty-three (32.9%) of the 
respondents have the patient call or proceed to the office or hospital without first re-
attempting the count. 
Limitations of the Study 
31 
Although the survey used for this study has been used before in another study and 
had been adapted according to the results of that study, an additional piece of information 
that may have been interesting to add would have been in which state the respondent 
practiced. The state of practice would possibly show if there were any regional variations 
in practice. Another interesting note is that some respondents when asked if they 
routinely screen would put no as an answer and in the explanation box, would state that 
they only screen at patient's request or other similar response. The wording on some of 
the questions may have been changed to "do you routinely offer" in order to get a more 
accurate response. Another limitation is that only 7 5 APN s responded to the survey. It is 
possible that only those who are comfortable with technology and computers responded 
to the survey. Another possible limitation is that those APNs who do routinely screen 
may be more inclined to complete the survey. The lack of any follow-up communication 
regarding the survey may have been responsible for the low response rate. 
Implications for Further Study 
Many areas exist for further study of obstetrical screening practices. Research 
could include asking providers which guidelines they use when ordering certain tests. 
The survey could be made available at national conferences on computers as well as 
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written to allow for greater number of respondents. Comparisons could be made between 
physicians and advanced practice nurses. 
Fetal movement monitoring is an area that lends itself to further study due to the 
lack of consistent information and quality research. Research might include more 
comprehensive surveys of advanced practice nurses as well as physicians focusing 
primarily on fetal movement monitoring. Research focusing on the relationship between 
decreased fetal movement and the results of subsequent non-stress testing and 
biophysical profile testing could provide valuable data about the efficacy and 
practicability of routinely asking women to monitor fetal movement. Actually being able 
to answer the question of whether maternal monitoring of fetal movement actually 
impacts intrauterine fetal death rates in term pregnancies is likely to be impractical, since 
the outcome is relatively rare. 
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Appendix A 
Online Survey 
Obstetric Screening Practices ofNurse-Midwives and Nurse Practitioners 
Laura Abney, a graduate student in the University ofNorth Florida master's program in 
nursing, is interested in understanding more about routine obstetrical screening practices 
of nurse-midwives with respect to maternal serum markers for fetal abnormalities, 
bacterial vaginosis, gestational diabetes, fetal kick counts, and group B Strep. The survey 
will take about 10 minutes to complete. This site is a secure one, and only the survey data 
are captured and recorded. We receive only the aggregate report, with no identifying data. 
Completion and submission of the survey indicates your willingness to participate. 
If you have any questions, or to request hard copies of the survey, you may contact Laura 
Abney (laurabuntley@bellsouth.net) or Kathy Bloom (kbloom@unf.edu). If you have 
questions about your rights as a research subject you may contact Nicole Sayers at the 
Research Compliance office at the University ofNorth Florida (620-2498). 
Instructions: Please check the applicable response that reflects your clinical practice 
related to obstetrical screening. 
Demographics Please share a little about yourself and your practice. 
1. What is your age? 
2. What is your gender? 
D Female 
D Male 
3. What is your highest level of education? 
D Bachelor's in nursing 
D Bachelor's in another field 
D Master's in nursing 
D Master's in another field: 
D Doctorate in nursing 
D Doctorate in another field 
4. What is your specialty? 
D Adult Nurse Practition~r 
D Family Nurse Practitioner 
D Nurse-Midwife 
D Women's Health Nurse Practitioner 
D Other: _______________ _ 
5. Are you certified in advanced practice? 
ONo 
0 Yes: By Whom? 
OACNM 
OACT. 
OANCC 
0 Other: ___________ _ 
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6. Do you hold membership in professional organizations for advanced practice nurses? 
[Check all that apply] 
0 American Academy ofNurse Practitioners 
0 American College ofNurse-Midwives 
0 American College ofNurse Practitioners 
0 Association of Reproductive Health Professionals 
0 National Association ofNurse Practitioners in Women's Health 
0 Other: _______________ _ 
7. Which of the following most accurately describes your practice [Choose ONE] 
0 Practice with OB/GYN physician(s) 
0 Practice with OB/GYN physician(s) and other nurse practitioners/nurse-
midwives 
0 Practice with Family Practice physician(s) 
0 Practice with Family Practice physician(s) and other nurse practitioners/nurse-
midwives 
0 Other: 
---
8. Approximately how many pregnant women do you see each year? 
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General Screening Practices 
9. Which of the following screening tests do you routinely order for or offer to all OB 
patients? 
Routinely First Third 
Test order Trimester Trimester Other (Specify) 
CBC 0 Yes ONo 0 Yes ONe 0 Yes ONo 
H&HOnly 0 Yes ONo 0 Yes ONe 0 Yes ONo 
RPR 0 Yes ONo 0 Yes ONe 0 Yes ONo 
Chlamydia 0 Yes ONo 0 Yes ONe 0 Yes 0 No 
Culture 
Gonorrhea 0 Yes ONo 0 Yes ONo 0 Yes ONe 
Culture 
HSV 0 Yes ONo 0 Yes ONo 0 Yes ONe 
Testing 
HIV Testing 0 Yes ONo 0 Yes ONe 0 Yes ONe 
Encouraged 
Pap Smear 0 Yes ONo 0 Yes ONo 0 Yes ONe 
Urine 0 Yes ONo 0 Yes 0 No 0 Yes ONe 
Culture 
10. Identify where the following screening tests are done for your OB patients: 
a. OB ultrasound 0 In my office 0 Referred out 
b. NST 0 In my office 0 Referred out 
c. Glucose testing 0 In my office 0 Referred out 
d. Hemoglobin 0 In my office 0 Referred out 
11. For which of the following does your practice have written protocols for routine 
screening of OB patients? 
0 Maternal Serum Markers ofF etal Abnormalities 
0 Bacterial Vaginosis 
0 Gestational Diabetes 
0 Group B Strep 
0 Fetal Kick Counts 
Screening for Maternal Serum Markers of Fetal Abnormalities 
12. Do you routinely order or offer screening to all OB patients for serum markers? 
0 No - go to question # 15 
0 Yes - go on to question # 13 
13. When do you do this screening? weeks gestation 
14. What test do you order? [Choose ONE] 
DAFP 
D Triple Screen 
D Triple Screen with cystic fibrosis 
D Quad Screen with cystic fibrosis 
D Other: ______________ _ 
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15. If you do not routinely order or offer screening to all OB patients for serum markers, 
under what conditions do you screen? ______________ _ 
Screening for Bacterial Vaginosis 
16. Do you routinely order or offer screening to all OB patients for Bacterial Vaginosis? 
D No- go to question# 20 
DYes- go on to question# 17 
17. When do you do this screening? [Check all that apply] 
D First trimester 
D Third trimester 
D Other: 
18. What diagnostic criteria do you use? [Check all that apply] 
D Nitrazene paper 
D Wetprep 
D Culture 
19. What treatment do you order for positive BV? [Choose the ONE you prescribe most 
frequently for first trimester and the ONE you choose most frequently after the first 
trimester]. 
D Metrogel 1 applicator per vagina HS x 5 days 
D First trimester D After the first trimester 
D Metronidazole PO 2 Gm x 1 dose 
D First trimester D After the first trimester 
D Metronidazole 250 mg PO TID x 7 days 
D First trimester D After the first trimester 
D Metronidazole 500 mg PO TID x 7 days 
D First trimester D After the first trimester 
D Clindamycin 300 mg PO BID x 7 days 
D First trimester D After the first trimester 
D Clindamycin cream 1 applicator/vagina HS x 7 days 
D First trimester D After the first trimester 
D Other: 
D First trimester 
D Nothing 
D First trimester 
D After the first trimester 
D After the first trimester 
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20. If you do not routinely order or offer screening to all OB patients for Bacterial 
Vaginosis, under what conditions do you screen? ____________ _ 
Screening for Gestational Diabetes 
21. Do you routinely order or offer screening to all OB patients for Gestational 
Diabetes? 
0 No - go to question # 28 
0 Yes - go on to question # 22 
22. When do you do this routine screening? ___ weeks gestation 
23. What risk factors do you use for an early screen? 
0 Obesity 
0 Previous history of GDM 
0 History of macrosomia 
0 Family history of diabetes 
0 Previous unexplained fetal death 
0 Previous birth of an infant with unexplained congenital abnormalities 
OOther: ________________________________________ __ 
24. What prep do you have for the 1 hour screen? 
0 Fasting 
0 Nonfasting 
25. What cut off do you use for the 1 hour screen 
0 135 
0 140 
OOther: ________________________________________ __ 
26. At what point do you refer to a perinatologist? 
0 With an abnormal 1 hour screen 
0 With an abnormal 3 hour test 
0 I do not refer, I treat women with gestational diabetes 
27. If you do not routinely order or offer screening to all OB patients for Gestational 
Diabetes, under what conditions do you screen?-------------------------
Group B Strep 
28. Do you routinely order or offer screening to all OB patients for Group B Strep? 
0 No- go to question# 28 
0 Yes - go on to question # 29 
29. Do you use the: 
0 Risk Factor Approach- go to question# 30 
0 Culture-Based Approach - go to question# 31 
30. If you use the Risk Factor Approach, for what conditions in pregnancy do you 
consider risk 
factors? [Check all that apply] 
D Previous child affected with GBS 
D Previous history of preterm labor or preterm PROM 
D Multifetal gestation 
D GBS UTI in pregnancy 
D Other: 
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31. Ifyou use the Culture-Based Approach, when do you do the culture? weeks 
gestation. 
32. From which site(s) do you obtain a screening culture? [Check all that applyl 
D Vagina 
D Cervix 
D Anorectal area 
D Urethra 
D Other: 
---------------------------------
33. If a positive screening culture is obtained from one of these sites, when do you treat 
(or when is treatment recommended)? 
D At the time of the positive result only 
D At the time of the positive result and in labor 
D In labor only 
Fetal Kick Counts 
34. Do you routinely recommend fetal kick counts for all OB patients? 
D No- go to question# 
D Yes- go to question# 35 
3 5. When do you have pregnant women begin kick counts? 
D 20-28 weeks gestation 
D 29-31 weeks gestation 
D 32-35 weeks gestation 
D 36-40 weeks gestation 
D Only if decreased movement 
D Only if high risk 
36. What instructions do you give about how to count fetal movements? Please be 
specific. 
3 7. What instructions do you give about what to do if there is a decrease? Please be 
specific. 
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Appendix C 
Recruitment E-mail or Postcard 
Laura Abney, a graduate student in the University ofNorth Florida master's program in 
nursing, is interested in understanding more about routine obstetrical screening practices 
of nurse-midwives with respect to matemal serum markers for fetal abnormalities, 
bacterial vaginosis, gestational diabetes, fetal kick counts, and group B Strep. 
Your name was chosen at random from the ACNM [NPWH] Member Directory. We 
have received permission from ACNM [NPWH] to use the member list for this purpose. 
The process is easy. Just log on to the Web site listed below and go to the appropriate 
survey. Your anonymity is completely assured. The survey will take approximately 10 
minutes to complete and your completion of the survey indicates your consent to 
participate in the research. The survey can be accessed through the following link: 
www.unf.edu/brooks. Just click on Best Practice Survey and you will be ready to go. 
Our goal is to complete data collection by September 15,2008. If you would prefer, we 
can mail you a hard copy of the survey along with a stamped and self-addressed return 
envelope. 
If you have any questions, or to request hard copies of the survey, you may contact Laura 
Abney (laurabuntley@bellsouth.net) or Kathy Bloom (kbloom@unf.edu). If you have 
questions about your rights as a research subject you may contact Nicole Sayers at the 
Research Compliance office at the University of North Florida (620-2498). 
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